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 ORIGINAL ARTICLE
Charting the Endometrial Cancer Care Pathway  
A Baseline Audit  
Jason Attard, Mark R Brincat, Charmaine Tanti, Nicole Buhagiar, Marie Claire Farrugia, 
Jean-Claude Farrugia, Stefan Laspina, Yves Muscat Baron, Danika Marmarà  
INTRODUCTION 
Longer waiting times from diagnosis to surgical resection have been 
found to negatively impact the overall survival and quality of life of 
women with endometrial cancer.  The Cancer Care Pathway 
Directorate adopted the UK National Waiting Times Monitoring 
Dataset Guidance, to improve the timeliness of services along the 
cancer care pathway.  From this, three key targets were identified: 1) 
Maximum 14-day wait from urgent GP referral for suspected cancer 
to first outpatient attendance (operational standard of 93%), 2) 
Maximum 31-day wait from decision to treat to first definitive 
treatment (operational standard of 96%), and 3) Maximum 62-day 
wait from urgent GP referral for suspected cancer to first treatment 
(operational standard of 85%).  The aim of this baseline audit was to 
chart the time-frames of the various stages in the endometrial cancer 
pathway of patients diagnosed with this disease between 2015 and 
2016 to assess for and identify delays in referral, investigation and 
care. 
METHODS 
A tool was developed following consultation with key 
stakeholders.  Data protection clearance was obtained.  Patient 
medical and oncology files, hospital databases, and MDT 
documentation for confirmed endometrial cancer cases were 
reviewed between September 2017 – March 2018. 
RESULTS 
A total of 101 endometrial cancer cases were included in the 
audit.  The proportion of cases which met the 14-day, 31-day and 62-
day wait KPIs operational standards were 39.1%, 81.2% and 17.2% 
respectively.  
CONCLUSION 
The endometrial cancer care pathway timeframes did not meet the 
KPIs operational standards.  Fast-track coordinators and nurse 
navigators could improve continuity and coordination of patient care. 
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INTRODUCTION 
Endometrial cancers constitute 7.3% of cancer 
cases in women in Malta with a five-year 
average of 72 new cases per year between 
2011 and 2015.  Uterine cancer is the main 
cause for 4.3% of cancer death in Maltese 
women with a five-year average of 17 deaths 
annually between 2011 and 2015.1  The 1-year 
and 5-year survival for uterine cancers 
diagnosed in 2000–2007 in Malta were 90.4% 
[95% confidence interval (CI) 86.9 – 94.1%] and 
80.2% (95% CI 73.9 – 86.9%) respectively.2  In a 
recent, population-based study, longer waiting 
times from diagnosis to surgical resection have 
been found to negatively impact the overall 
survival of women with endometrial cancer.3  
Furthermore, longer waiting times have been 
found to have a nocebo effect,4 and poorer 
quality of life and patient satisfaction.5   
The Cancer Care Pathway Directorate, which 
was established in 2014, adopted the UK 
National Waiting Times Monitoring Dataset 
Guidance, to improve the timeliness of 
services along the cancer care pathway.6  From 
this, three key targets were identified: 
• Maximum two weeks from urgent GP 
referral for suspected cancer to first 
outpatient attendance [Operational 
Standard of 93%]. 
• Maximum one month (31 days) from 
decision to treat to first definitive 
treatment [Operational Standard of 96%]. 
• Maximum two months (62 days) from 
urgent GP referral for suspected cancer to 
first treatment [Operational Standard of 
85%]. 
The New Zealand Cancer Plan: Better, Faster 
Cancer Care 2015-2018 and the Australian 
Hospital Performance: Cancer surgery waiting 
times in public hospitals in 2012-13 have 
identical key targets.7-8 
Timeliness in histopathology reporting 
ensures an appropriate level of patient care.  
The Royal College of Pathologists have 
produced a set of KPIs, two of which are 
related to histopathology reporting 
timeframes.9 
1. Histopathology diagnostic biopsy 
turnaround times: Percentage of 
diagnostic biopsies reported, confirmed 
and authorised within 7 days of biopsy 
(RCPath Challenge: 80% by April 2012 
increased to 90% by April 2014). 
2. Overall Histopathology reporting 
turnaround times: Percentage of all 
histopathology and diagnostic cytology 
final reports available within 10 calendar 
days of procedure (RCPath Challenge: 80% 
by April 2012 increased to 90% by April 
2014).   
According to the UK National Waiting Times 
Monitoring Dataset Guidance, all subsequent 
treatments for primary and recurrent cancer 
need to have a 31-day period recorded.6  The 
operational standards for subsequent surgery, 
drug treatment, and radiotherapy are 94%, 
98% and 94%, respectively. 
The aim of this baseline audit was to chart the 
time-frames of the various stages in the 
endometrial cancer pathway of patients 
diagnosed with this disease between 2015 and 
2016 to assess for and identify delays in 
referral, investigation and care. 
 
METHODOLOGY 
A retrospective audit was conducted to chart 
the endometrial cancer pathway. The study 
sample was obtained from the histopathology 
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department information officer using the 
Laboratory Information System (LIS) of Mater 
Dei Hospital (MDH) and comprised patients 
who were diagnosed with cancer in 2015 and 
2016. 
 The data collection tool was developed 
following consultation with key stakeholders 
in the field including consultant 
gynaecologists, as well as doctors and the 
Cancer Care Pathways Directorate. 
Data protection clearance was obtained prior 
to the start of data collection which took place 
between September 2017 and February 2018.  
Data was retrieved from patients’ personal 
medical and oncology files at MDH and Sir 
Anthony Mamo Oncology Centre, iSoft Clinical 
Manager, chemotherapy and radiotherapy 
databases, and email records for 
multidisciplinary team (MDT) meeting. 
Descriptive and inferential analyses were 
performed through a combination of 
Microsoft Office Professional Plus 2010 Excel, 
and IBM SPSS Statistics version 22.  In view of 
the heavy right skewed distributions for the 
various timeframes, medians and quartiles 
were preferentially used for the descriptive 
statistics.  Tests performed were Fisher’s Exact 
test and binary logistic regression. 
RESULTS 
Sample overview 
The original dataset provided by the 
histopathology department information 
officer consisted of a total of 491 patients. 285 
duplicate entries were removed.  A total of 101 
patient medical records were available and 
included in the final analysis presented in the 
report.  The mean age at diagnosis of this 
group of patients was 61 years (standard 
deviation = 8.8 years, median = 60 years, range 
= 42-86 years).  Diagnostic methods and cancer 
characteristics are summarised in Table 1. 
The initial point of contact with the health care 
system including the date was identified in 94 
out of 101 cases (93.1%) of endometrial cancer 
and are summarised in Table 2. 
 
Table 1   Diagnostic methods and cancer 
characteristics 
Variables n % 
Biopsy method   
Intrauterine endometrial sampler 19 18.8% 
D&C 76 75.2% 
Unknown 6 5.9% 
Preoperative imaging   
CT 54 53.5% 
MRI 2 2.0% 
Both 1 1.0% 
None 44 43.6% 
Histological diagnosis   
Endometrioid 92 91.1% 
Other 9 8.9% 
FIGO grading   
G1 66 65.3% 
G2 19 18.8% 
G3 16 15.8% 
FIGO staging   
FIGO IA 67 66.4% 
FIGO IB 18 17.8% 
FIGO II 8 7.9% 
FIGO IIIA 1 1.0% 
FIGO IIIB 4 4.0% 
FIGO IIIC1 1 1.0% 
Unknown 2 2.0% 
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KEY PERFORMANCE INDICATORS (KPI) 
The distribution of the number of days waiting 
for the KPI timeframes and the GOP new case 
appointment to post-biopsy GOP follow up 
(decision to treat) appointment timeframe 
were summarised in Table 3. 
‘14-day wait’ from referral to specialist review 
at outpatients: 34 out of 87 patients with 
endometrial cancer (39.1%) were seen by a 
specialist at GOP within two weeks of referral.  
52 out of 87 patients with endometrial cancer 
(59.8%) were seen by a specialist either at GOP 
or in the initial contact in private practice 
within two weeks. 
‘31-day wait’ from decision to treat to receipt 
of first treatment: 69 out of 85 patients 
(81.2%) with endometrial cancer received first 
treatment following decision to treat within a 
31-day timeframe. 
‘62-day wait’ from referral to receipt of first 
treatment: Only 16 out of 93 patients (17.2%) 
with endometrial cancer received first 
treatment following referral within 62 days. 45 
out of 93 patients with endometrial cancer 
(48.4%) received first treatment after being 
seen by a specialist either at GOP or in the 
initial contact in private practice within 62 
days. 
The ‘14-day wait’ and ‘62-day wait’ key 
performance indicator for the endometrial 
cancer care pathway could be analysed in 
those cases where date “day zero” and the 
date of the GOP new case appointment or first 
treatment were both known. 
INTRADEPARTMENTAL TIMEFRAMES 
The distribution of the number of days from 
procedure to histology report were 
summarised in Table 4. 
Histopathology diagnostic biopsy turnaround 
times: 50 out of 94 histopathology reports 
(53.2%) were available within 7 calendar days 
of the diagnostic biopsy.   
Histopathology surgical resection reporting 
turnaround times: 58 out of 99 histopathology 
reports (58.6%) were available within 10 
calendar days of surgical resection. 
The distribution of the number of days from 
the first oncology review to oncology 
treatment were summarised in Table 5.  9 out 
of 27 cases (33.3%) and 9 out of 10 cases (90%) 
received radiotherapy and chemotherapy 
respectively within 31 days from the first 
oncological review.  Cases requiring 
radiotherapy had longer waits for treatment 
when compared to cases requiring 
chemotherapy from oncological review.  
However, 9 cases requiring radiotherapy 
received treatment after chemotherapy.  After 
excluding these cases, 8 out of 18 cases 
(44.4%) received radiotherapy within 31 days 
from the first oncological review. 
 
Table 2   Initial point of contact with the 
health care system 
Initial Contact with the Health 
System (Day Zero) 
n % 
GP referral to GOP 41 40.6% 
GP referral to private 
gynaecologist 1 1.0% 
GP referral to A&E 6 5.9% 
Self-referral to A&E 9 8.9% 
Private gynaecologist referral to 
GOP 37 36.6% 
Unknown 7 6.9% 
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Table 3   Distribution of the number of days waiting for the three KPIs and GOP new case 
 appointment to decision to treat timeframe 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4   Distribution of the number of days from procedure to histology report 
Number of Days from: n Mean SD Median 
1st 
Quartile 
3rd 
Quartile 
Diagnostic biopsy to 
histology report 
94 9.4 6.1 7.0 6.0 11.3 
Surgical resection to 
histology report 
99 12.0 6.8 10.0 7.0 15.0 
 
 
 
Table 5   Distribution of the number of days from first oncology review to oncology treatment 
Number of Days from: n Mean SD Median 
1st 
Quartile 
3rd 
Quartile 
First oncology review to 
radiotherapy 
27 75.6 70.0 41.0 28.0 114.5 
First oncology review to 
chemotherapy 
10 24.6 19.1 25.0 10.0 31.0 
 
 
 
Number of Days from: n Mean SD Median 
1st 
Quartile 
3rd 
Quartile 
Day Zero to GOP new case 87 32.5 27.5 25.0 9.0 54.0 
Decision to treat to first 
treatment 
85 23.2 25.5 15.0 10.0 27.5 
Day Zero to first treatment 93 122.7 95.2 110.0 66.5 146.0 
GOP new case to decision 
to treat 
80 74.4 93.3 49.0 35.0 71.8 
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Table 6   Distribution of the number of days of interdepartmental transitioning 
 
 
GOP Appointment to Procedure Timeframes 
Number of Days from: n Mean SD Median 1st Quartile 3rd Quartile 
GOP new case to diagnostic 
biopsy 
75 56.1 92.1 26.0 17.0 48.0 
Post-biopsy GOP follow up 
(decision to treat) to surgical 
resection 
85 23.2 25.5 15.0 10.0 27.5 
 
Histology Report to GOP Appointment Timeframes 
Number of Days from: n Mean SD Median 1st Quartile 3rd Quartile 
Biopsy result to GOP follow-up 86 16.4 12.0 14.0 8.8 20.3 
Surgical resection histology 
report to GOP follow-up 
94 21.5 14.4 18.0 12.0 25.5 
 
Preoperative Imaging 
Number of Days from: n Mean SD Median 1st Quartile 3rd Quartile 
Post-biopsy GOP follow up 
(decision to treat) to imaging 
46 8.5 15.3 4.0 0.0 9.8 
Imaging to surgical resection 52 7.4 6.1 6.0 3.0 11.0 
 
Multidisciplinary Team Meetings 
Number of Days from: n Mean SD Median 1st Quartile 3rd Quartile 
Biopsy result to MDT meeting 20 31.9 26.3 24.0 12.0 42.0 
Surgical resection histopathology 
report to MDT meeting 
35 20.3 14.6 16.0 8.0 36.0 
 
Oncology referral 
Number of Days from: n Mean SD Median 1st Quartile 3rd Quartile 
Oncology referral to first 
oncology review 
53 11.2 7.4 10.0 6.5 14.0 
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INTERDEPARTMENTAL TIMEFRAMES 
The distribution of the number of days of 
interdepartmental transitioning were 
summarised in Table 6.  
A Fisher’s Exact test showed that the initial 
contact with the health system was associated 
with statistically significant differences with 
the 14-day wait KPI (p=0.005).  Binary logistic 
regression showed that when compared to 
private gynaecologist referral, cases which 
were referred to GOP by GP referral were 
statistically significantly more likely to breach 
the 14-day wait KPI (see Table 7).  When 
compared to GP referral, cases which were 
referred to A&E, went directly to A&E or were 
referred to GOP by a private gynaecologist 
were statistically significantly less likely to 
breach the 14-day wait KPI (p<0.05) (see Table 
8). 
A Fisher’s Exact test showed that the initial 
contact with the health system was associated 
with statistically significant differences with 
the 62-day wait KPI (p=0.026).  Binary logistic 
regression showed that when compared to 
private gynaecologist referral to GOP, cases 
which went to directly to A&E were statistically 
significantly less likely to breach the 62-day 
wait KPI (see Table 9).  The single case referred 
by GP to a private gynaecologist was excluded 
from the analysis.  When compared to GP 
referral to GOP, both GP referral to A&E and 
self-referral to A&E were less likely to breach 
the 62-day wait KPI (p<0.05) (see Table 10). 
A Fisher’s Exact test showed that there were 
no statistically significant differences between 
initial contact with the health system and the 
31-day wait KPI (p=0.668).  The single case 
referred by GP to a private gynaecologist was 
excluded from the analysis. 
 
 
 
Table 7   Binary logistic regression between initial contact with the health system and 14-day wait              
KPI with private gynaecologist referral to GOP as the reference category 
 
Initial Contact with the Health System n 
Odds 
Ratio 
95% CI 
p value 
Lower Upper 
GP Referral to GOP 41 3.358 1.244 9.065 0.017 
GP Referral to A&E 5 0.236 0.024 2.330 0.217 
Self-Referral to A&E 6 0.472 0.076 2.921 0.420 
Private gynaecologist referral to GOP* 35 - - - 0.015 
*Reference category 
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Table 8   Binary logistic regression between initial contact with the health system and 14-day wait 
KPI with GP referral to GOP as the reference category 
Initial Contact with the Health System n Odds Ratio 
95% CI 
p value 
Lower Upper 
GP Referral to GOP* 41 - - - 0.015 
GP Referral to A&E 5 0.070 0.007 0.710 0.024 
Self-Referral to A&E 6 0.141 0.022 0.896 0.038 
Private gynaecologist referral to GOP 35 0.298 0.110 0.804 0.017 
*Reference category 
 
Table 9   Binary logistic regression between initial contact with the health system and 62-day wait 
KPI with private gynaecologist referral to GOP as the reference category 
Initial Contact with the Health System n Odds Ratio 
95% CI 
p value 
Lower Upper 
GP Referral to GOP 41 4.707 0.91 24.345 0.065 
GP Referral to A&E 6 0.483 0.073 3.187 0.450 
Self-Referral to A&E 9 0.193 0.041 0.912 0.038 
Private gynaecologist referral to GOP* 36 - - - 0.001 
*Reference category 
 
Table 10   Binary logistic regression between initial contact with the health system and 62-day wait 
KPI with private gynaecologist referral to GOP as the reference category 
Initial Contact with the Health System n Odds Ratio 
95% CI 
p value 
Lower Upper 
GP Referral to GOP* 41 - - - 0.026 
GP Referral to A&E 6 0.103 0.011 0.988 0.044 
Self-Referral to A&E 9 0.041 0.006 0.284 0.001 
Private gynaecologist referral to GOP 36 0.212 0.041 1.099 0.065 
*Reference category 
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DISCUSSION 
The results of this audit need to be considered 
in the light of several limitations.  The 
convenience sampling and number of cases 
included may affect the generalisability of this 
audit.  We estimate 72 new cases of 
endometrial cancer per year; the sample size 
analysed is 101 cases over the two-year period.  
The medical files of patients diagnosed with 
endometrial cancer in 2015 and 2016 who had 
died before the data collection phase of the 
audit could not be analysed.  As this audit was 
retrospective, it was prone to missing data 
such as delay to treatment due to medical 
reasons.  Additionally, it is unknown whether 
patients had their appointments rescheduled 
following non-attendance.  Moreover, it was 
difficult to link the oncology consultation 
which lead to the first oncological treatment.  
Therefore, the first oncological new case 
appointment was used.  This may have 
overestimated the oncology review to 
oncology treatment timeframes.  Finally, the 
quality of the information provided in the 
ticket of referral written by a GP was not 
assessed in the current audit, and it should be 
acknowledged that this information may 
influence the urgency with which a case is 
reviewed at GOP. 
The 14-day wait KPI, allowing a maximum two 
weeks from referral for suspected cancer to 
first outpatient attendance, was well below 
the accepted operational standard of 93% as 
described in the UK National Waiting Times 
Monitoring Dataset Guidance.  When 
compared with GP referral to GOP, GP referral 
to A&E, self-referral to A&E, and private 
gynaecologist referral to GOP are less likely to 
exceed the 14-day wait KPI.  Measures that 
could decrease the number of days from time 
of referral to GOP new case appointment 
include further education for primary care 
doctors and immediate vetting of referral 
letters.10  
The 31-day wait KPI, allowing a maximum one 
month from decision to treat to first definitive 
treatment, was below the accepted 
operational standard of 96%.  Preoperative 
imaging and post-biopsy MDT meetings were 
not found to delay definitive surgical 
treatment.  Medical problems and other 
conditions which pose a problem for 
anaesthesia are possible causes for exceeding 
the 31-day wait KPI. Interdepartmental fast-
track channels between gynaecology, 
anaesthesia and medical specialities would 
help improve this KPI. 
The 62-day wait KPI, allowing a maximum two 
months from referral for suspected cancer to 
first treatment, was well below the accepted 
operational standard of 85%.  When compared 
with GP referral to GOP, self-referral to A&E 
and GP referral to A&E are less likely to exceed 
the 62-day wait KPI.  Private gynaecologist 
referral to GOP appeared less likely to breach 
the 62-day wait, however it did not reach 
statistical significance.  Of note, the 62-day 
wait KPI was markedly worse when compared 
with the 14-day wait KPI with a difference of 
21.9%.  This finding prompted an analysis of 
the overall and interim inter- and intra-
departmental timeframes between the GOP 
new case appointment and post-biopsy GOP 
follow up (decision to treat) appointment.  
Based on the three KPIs, the overall GOP new 
case to decision to treat timeframe should be 
17 calendar days, assuming a maximum of 14 
days from referral to GOP.  However, based on 
the medians described in the results, there are 
potential delays in having a diagnostic biopsy, 
histology reporting and having a follow up 
appointment at GOP.  Measures to decrease 
the time to diagnostic biopsy include training 
GPs to do intrauterine endometrial sampler 
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biopsies and setting up a one-stop shop for 
women referred with post-menopausal 
bleeding for hysteroscopy and curettage 11.  
The post-menopausal bleeding (PMB) clinic at 
Mater Dei Hospital started in 2018.  GP referral 
to the PMB clinic will most likely improve both 
14-day and 62-day wait KPIs.  The 
histopathology department can flag biopsies 
which are suspicious for cancer to be able to 
prioritise accordingly.  Furthermore, once the 
histology report is ready, a follow up GOP 
appointment should be scheduled for the next 
outpatient session. 
Up to three-fourths of cases referred to 
oncology had an oncological review within two 
weeks.  Waiting times for radiotherapy 
treatment following oncological review were 
below the operational standard.  Waiting times 
for chemotherapy treatment following 
oncology review were just below the 
operational standard.  Measures to improve 
the waiting times for radiotherapy treatment, 
through restructuring of the radiotherapy 
department have been implemented in the 
interim between the audit years 2015 and 
2016 and April 2018. 
More research needs to be done to address the 
important limitations previously described.  
These include prospective and qualitative 
studies.  Furthermore, there is a dire need for 
a robust business process across and within 
primary and secondary healthcare supported 
by an information technology infrastructure to 
readily track patients as they navigate the 
health care system.  Such processes and 
infrastructure would make it easier to retrieve 
data to re-audit and close the audit cycle. 
A fast-track coordinator and a nurse navigator 
would further ensure better continuity and 
coordination of patient care by tracking the 
patient from referral to diagnosis and from 
diagnosis onward respectively. 
CONCLUSION 
The endometrial cancer care pathway 
timeframes did not meet the 14-day, 31-day 
and 62-day wait KPIs operational standards.  
Seeking a private gynaecological consultation 
or referral to the emergency department have 
been shown to be the most efficient pathways 
for patients to get timely investigation and 
treatment when compared with GP referral to 
gynaecological outpatients.  The introduction 
of the post-menopausal bleeding clinic is a 
step in the right direction to improve on these 
outcomes and decrease the load from 
emergency services. 
Further recommendations include: 
• Fast-track referral by GPs to secondary 
health care services for women with 
symptoms suspicious for endometrial 
cancer. 
• Setting evidence-based targets and 
timelines which best suit our health care 
system. 
• Communicate these targets and timelines 
to key stakeholders (namely primary 
health care and the departments of 
obstetrics and gynaecology, 
histopathology, radiology, outpatients 
and oncology). 
• Engaging key workers to track patients 
along the care pathway. 
• Re-audit following changes in the health 
service. 
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